Tiotropium bromide - Glenmark Pharmaceuticals

Drug Profile

Tiotropium bromide - Glenmark Pharmaceuticals

Alternative Names: GSP 304

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Antiasthmatics; Antibronchitics; Epoxy compounds; Esters; Small molecules; Thiophenes; Tropanes
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 31 Jul 2017 Glenmark completes a phase II trial in Chronic obstructive pulmonary disease (In adults, In the elderly) in USA (Inhalation) (NCT03118765)
  • 24 Mar 2017 Phase-II clinical trials in Chronic obstructive pulmonary disease (In adults, In the elderly) in USA (Inhalation) (NCT03118765)
  • 07 Mar 2017 Glenmark Pharmaceuticals plans a phase II trial for Chronic obstructive pulmonary disease in India (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top